[Form 3/A] Inhibikase Therapeutics, Inc. Amended Initial Statement of Beneficial Ownership
Inhibikase Therapeutics director Aurentz Vincent reported beneficial ownership of 765,895 shares of common stock in an amended Form 3/A. These shares were issued as merger consideration in connection with the acquisition of CorHepta Pharmaceuticals completed on 02/21/2025 and were added to an earlier Form 3 filed 02/25/2025.
Of the 765,895 shares, 127,649 vested on the closing date, 382,947 will vest on the first anniversary of the closing date, and 255,299 are contingent: 25% of that tranche vests upon achievement of a specified milestone and 75% vests on the first anniversary, subject to continued service; if the milestone is not achieved by the first anniversary, all 255,299 shares are forfeited.
Aurentz Vincent, direttore di Inhibikase Therapeutics, ha dichiarato il possesso beneficiario di 765.895 azioni ordinarie in un emendamento al Modulo 3/A. Queste azioni sono state emesse come corrispettivo della fusione relativa all’acquisizione di CorHepta Pharmaceuticals completata il 21/02/2025 e sono state aggiunte a un Modulo 3 presentato in precedenza il 25/02/2025.
Delle 765.895 azioni, 127.649 sono maturate alla data di chiusura, 382.947 matureranno al primo anniversario della chiusura e 255.299 sono condizionate: il 25% di questa tranche matura al raggiungimento di uno specifico traguardo e il 75% matura al primo anniversario, subordinatamente al proseguimento del servizio; se il traguardo non viene raggiunto entro il primo anniversario, tutte le 255.299 azioni saranno revocate.
Aurentz Vincent, director de Inhibikase Therapeutics, informó la propiedad beneficiaria de 765.895 acciones comunes en una enmienda al Formulario 3/A. Estas acciones se emitieron como contraprestación por la fusión relacionada con la adquisición de CorHepta Pharmaceuticals completada el 21/02/2025 y se añadieron a un Formulario 3 presentado anteriormente el 25/02/2025.
De las 765.895 acciones, 127.649 se consolidaron en la fecha de cierre, 382.947 se consolidarán en el primer aniversario del cierre y 255.299 son contingentes: el 25% de ese tramo se consolida al alcanzarse un hito específico y el 75% se consolida en el primer aniversario, sujeto a la continuidad del servicio; si el hito no se alcanza para el primer aniversario, las 255.299 acciones se perderán.
Inhibikase Therapeutics의 이사 Aurentz Vincent는 수정된 Form 3/A에서 765,895주의 보유 이익을 보고했습니다. 이 주식들은 2025년 2월 21일 완료된 CorHepta Pharmaceuticals 인수와 관련된 합병 대가로 발행되었으며, 2025년 2월 25일 제출된 최초 Form 3에 추가되었습니다.
765,895주 중 127,649주는 종결일에 확정(vested)되었고, 382,947주는 종결일의 첫 번째 기념일에 확정되며, 255,299주는 조건부입니다: 해당 트랜치의 25%는 특정 목표 달성 시 확정되고 75%는 첫 기념일에 서비스 유지 조건 하에 확정됩니다; 만약 목표가 첫 기념일까지 달성되지 않으면 255,299주 전부가 몰수됩니다.
Aurentz Vincent, administrateur d'Inhibikase Therapeutics, a déclaré la propriété bénéficiaire de 765 895 actions ordinaires dans un Formulaire 3/A modifié. Ces actions ont été émises en contrepartie de la fusion liée à l’acquisition de CorHepta Pharmaceuticals finalisée le 21/02/2025 et ont été ajoutées à un Formulaire 3 antérieurement déposé le 25/02/2025.
Sur les 765 895 actions, 127 649 ont acquis le droit (vested) à la date de clôture, 382 947 deviendront acquises au premier anniversaire de la clôture et 255 299 sont conditionnelles : 25 % de cette tranche devient acquise à l’atteinte d’un jalon spécifié et 75 % au premier anniversaire, sous réserve de la poursuite du service ; si le jalon n’est pas atteint avant le premier anniversaire, les 255 299 actions seront annulées.
Inhibikase Therapeutics-Direktor Aurentz Vincent meldete in einer berichtigten Form 3/A den wirtschaftlichen Eigentum an 765.895 Stammaktien. Diese Aktien wurden als Fusionsgegenleistung im Zusammenhang mit der Übernahme von CorHepta Pharmaceuticals ausgegeben, die am 21.02.2025 abgeschlossen wurde, und wurden einem zuvor am 25.02.2025 eingereichten Form 3 hinzugefügt.
Von den 765.895 Aktien waren 127.649 zum Abschlussdatum erworben (vested), 382.947 werden am ersten Jahrestag des Abschlusses erworben, und 255.299 sind bedingt: 25 % dieses Teils werden beim Erreichen eines spezifischen Meilensteins erworben und 75 % am ersten Jahrestag, vorbehaltlich fortgesetzter Tätigkeit; wird der Meilenstein bis zum ersten Jahrestag nicht erreicht, verfallen alle 255.299 Aktien.
- Shares issued as merger consideration demonstrate alignment of the reporting person with the combined company
- 127,649 shares vested on the closing date, providing immediate alignment and value realization
- 382,947 shares scheduled to vest on first anniversary, concentrating near-term, time-based alignment
- 255,299 shares are milestone-contingent and subject to forfeiture if the milestone is not achieved by the first anniversary
- Amendment was required to include omitted shares, indicating an earlier disclosure omission
Insights
TL;DR: Director received a material equity grant tied to a Feb 21, 2025 acquisition; most shares vest within one year.
The filing documents a non-cash merger consideration issuance of 765,895 shares to a reporting director following the CorHepta acquisition. Immediate economic alignment is shown by 127,649 shares vested at closing and a further 382,947 scheduled to vest on the one-year anniversary, concentrating near-term dilution timing. The remaining 255,299 shares are milestone-contingent with forfeiture risk, which limits guaranteed dilution. This is a routine executive/director post-acquisition equity allocation rather than operational financial disclosure.
TL;DR: Amendment corrects an omission; vesting terms include service and milestone conditions with potential forfeiture.
The amended Form 3 clarifies previously omitted shares, reflecting a corrective disclosure practice. Vesting structure mixes immediate vesting, time-based vesting, and milestone-contingent vesting, aligning incentives to retention and achievement of a stated milestone. The amendment itself signals a filing oversight that was corrected; the substance shows standard post-merger equity treatment for a sellers' representative now serving as a director.
Aurentz Vincent, direttore di Inhibikase Therapeutics, ha dichiarato il possesso beneficiario di 765.895 azioni ordinarie in un emendamento al Modulo 3/A. Queste azioni sono state emesse come corrispettivo della fusione relativa all’acquisizione di CorHepta Pharmaceuticals completata il 21/02/2025 e sono state aggiunte a un Modulo 3 presentato in precedenza il 25/02/2025.
Delle 765.895 azioni, 127.649 sono maturate alla data di chiusura, 382.947 matureranno al primo anniversario della chiusura e 255.299 sono condizionate: il 25% di questa tranche matura al raggiungimento di uno specifico traguardo e il 75% matura al primo anniversario, subordinatamente al proseguimento del servizio; se il traguardo non viene raggiunto entro il primo anniversario, tutte le 255.299 azioni saranno revocate.
Aurentz Vincent, director de Inhibikase Therapeutics, informó la propiedad beneficiaria de 765.895 acciones comunes en una enmienda al Formulario 3/A. Estas acciones se emitieron como contraprestación por la fusión relacionada con la adquisición de CorHepta Pharmaceuticals completada el 21/02/2025 y se añadieron a un Formulario 3 presentado anteriormente el 25/02/2025.
De las 765.895 acciones, 127.649 se consolidaron en la fecha de cierre, 382.947 se consolidarán en el primer aniversario del cierre y 255.299 son contingentes: el 25% de ese tramo se consolida al alcanzarse un hito específico y el 75% se consolida en el primer aniversario, sujeto a la continuidad del servicio; si el hito no se alcanza para el primer aniversario, las 255.299 acciones se perderán.
Inhibikase Therapeutics의 이사 Aurentz Vincent는 수정된 Form 3/A에서 765,895주의 보유 이익을 보고했습니다. 이 주식들은 2025년 2월 21일 완료된 CorHepta Pharmaceuticals 인수와 관련된 합병 대가로 발행되었으며, 2025년 2월 25일 제출된 최초 Form 3에 추가되었습니다.
765,895주 중 127,649주는 종결일에 확정(vested)되었고, 382,947주는 종결일의 첫 번째 기념일에 확정되며, 255,299주는 조건부입니다: 해당 트랜치의 25%는 특정 목표 달성 시 확정되고 75%는 첫 기념일에 서비스 유지 조건 하에 확정됩니다; 만약 목표가 첫 기념일까지 달성되지 않으면 255,299주 전부가 몰수됩니다.
Aurentz Vincent, administrateur d'Inhibikase Therapeutics, a déclaré la propriété bénéficiaire de 765 895 actions ordinaires dans un Formulaire 3/A modifié. Ces actions ont été émises en contrepartie de la fusion liée à l’acquisition de CorHepta Pharmaceuticals finalisée le 21/02/2025 et ont été ajoutées à un Formulaire 3 antérieurement déposé le 25/02/2025.
Sur les 765 895 actions, 127 649 ont acquis le droit (vested) à la date de clôture, 382 947 deviendront acquises au premier anniversaire de la clôture et 255 299 sont conditionnelles : 25 % de cette tranche devient acquise à l’atteinte d’un jalon spécifié et 75 % au premier anniversaire, sous réserve de la poursuite du service ; si le jalon n’est pas atteint avant le premier anniversaire, les 255 299 actions seront annulées.
Inhibikase Therapeutics-Direktor Aurentz Vincent meldete in einer berichtigten Form 3/A den wirtschaftlichen Eigentum an 765.895 Stammaktien. Diese Aktien wurden als Fusionsgegenleistung im Zusammenhang mit der Übernahme von CorHepta Pharmaceuticals ausgegeben, die am 21.02.2025 abgeschlossen wurde, und wurden einem zuvor am 25.02.2025 eingereichten Form 3 hinzugefügt.
Von den 765.895 Aktien waren 127.649 zum Abschlussdatum erworben (vested), 382.947 werden am ersten Jahrestag des Abschlusses erworben, und 255.299 sind bedingt: 25 % dieses Teils werden beim Erreichen eines spezifischen Meilensteins erworben und 75 % am ersten Jahrestag, vorbehaltlich fortgesetzter Tätigkeit; wird der Meilenstein bis zum ersten Jahrestag nicht erreicht, verfallen alle 255.299 Aktien.